

**GOVERNMENT OF INDIA  
MINISTRY OF AYUSH**

**RAJYA SABHA  
UNSTARRED QUESTION NO. 163  
TO BE ANSWERED ON 30.11.2021**

**PROMOTION OF BETTER QUALITY AYUSH PRODUCTS**

**163. SHRI HARNATH SINGH YADAV:  
LT.GEN. (DR.) D. P. VATS (RETD.):**

Will the Minister of **AYUSH** be pleased to state:

- (a) whether it is a fact that the Ministry is trying to promote better quality AYUSH products on a larger scale for maximum benefit of consumers;
- (b) if so, the challenges which Ministry is facing in promoting better products for wider use by the consumers;
- (c) whether there have been cases where malpractices have been detected in manufacturing different AYUSH medicines; and
- (d) if so, the actions/measures that have been taken and if not, the reasons therefor?

**ANSWER  
THE MINISTER OF AYUSH  
(SHRI SARBANANDA SONOWAL)**

(a) and (b): Yes, Ministry of AYUSH is working on the components of AYUSH education, development of Infrastructure, development of drug related monographs, Pharmacopeias, maintenance of data of ASU & H drug manufacturers and their licenses etc. For this different schemes are implemented. In this regard financial support is provided through specific Central Schemes for AYUSH related research, Information-Education-Communication (IEC) activities including seminars, workshops, conferences etc, public health interventions, development of Centers of Excellence, upgrading of drug testing labs, upgrading ASU & H drug manufacturing firms.

(c) and (d): No such instances regarding malpractices, have been brought to the notice of the Ayush Ministry so far. To prevent such malpractices, as preemptive steps Ministry of Ayush has introduced Good Manufacturing Practices (GMP) under schedule T for ASU drugs and under Schedule M1 for Homeopathic medicines apart from quality standards of drugs prescribed by the Pharmacopoeia Commission of Indian medicine and Homoeopathy (PCIM&H) for ASU & H medicines. To monitor the same Pharmaco-vigilance cells are set up in the country to have check on such instances, adverse Drug Reactions and surveillance of misleading advertisements.